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Abstract
Our recent studies have shown that annexin II, expressed on the cell surface of osteoblasts, plays an important role in
the adhesion of hematopoietic stem cells (HSCs) to the endosteal niche. Similarly, prostate cancer (PCa) cells express
the annexin II receptor and seem to use the stem cell niche for homing to the bone marrow. The role of the niche is
thought to be the induction and sustenance of HSC dormancy. If metastatic PCa cells occupy a similar or the same
ecological niche as HSCs, then it is likely that the initial role of the HSC niche will be to induce dormancy in metastatic
cells. In this study, we demonstrate that the binding of PCa to annexin II induces the expression of the growth arrest–
specific 6 (GAS6) receptors AXL, Sky, and Mer, which, in the hematopoietic system, induce dormancy. In addition,
GAS6 produced by osteoblasts prevents PCa proliferation and protects PCa from chemotherapy-induced apoptosis.
Our results suggest that the activation of GAS6 receptors on PCa in the bone marrow environment may play a critical
role as a molecular switch, establishing metastatic tumor cell dormancy.
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Introduction
Nearly 10% of patients whose conditions are diagnosed as PCa initially
present with bone metastasis and almost all patients who die of prostate
cancers (PCas) have skeletal involvement [1]. Therefore, identifying the
mechanisms that control bone metastasis is of great consequence to
facilitate the design of therapeutics aimed at decreasing metastatic risk
and/or their complications.
The metastatic process is similar to “homing” behavior of hemato-
poietic stem cells (HSCs) to the bone marrow. In marrow, HSCs reside
in an area that is defined as the stem cell “niche.” Identification of the
HSC niche in marrow has been an active area of investigation. Works
in this field have demonstrated that several molecules expressed by
osteoblasts [2–6] and endothelial cells [7] play critical roles in niche
selection. Recently, it was shown that 1) the engraftment of HSCs
in lethally irradiated animals during experimental bone marrow trans-
plantation and 2) PCa metastasis to the marrow are dependent on
many of the same molecules [8,9].
Several studies have shown that disseminated cells shed from a pri-
mary tumor may lie dormant in distant tissues for long periods before
they can be activated to form metastases [10–12]. At present, there is
little information on how dormancy is induced or what leads to the
activation of the dormant cells. One hypothesis worth considering is
that molecules that induce HSC dormancy are likely to induce dor-
mancy of metastatic PCa cells. Where adhesion molecules and secreted
factors derived from the HSC niche are thought to regulate HSC self-
renewal, proliferation, and differentiation [13].
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One protein in high abundance in the marrow is annexin II
(Anxa2) [14]. Our recent work has shown that Anxa2 expressed by
osteoblasts and endothelial cells plays a critical role in HSC niche
selection [15]. More recently, we found that Anxa2 and the Anxa2
receptor (Anxa2r) axis plays a crucial role in establishing bone metas-
tases of PCa [9] by regulating PCa migration, adhesion, and growth
in the bone marrow [9]. Blocking Anxa2 or Anxa2r limited short-
term and long-term localization of human PCa in murine models,
further demonstrating the role of this axis [9].
To further explore the role that Anxa2 plays in the interactions of
both PCa and HSCs and the endosteal niche, we added purified
Anxa2 protein to PCa cells in vitro. Gene expression microarray analy-
sis demonstrated that expression of the receptor tyrosine kinase (RTK)
AXL (from the Greek word anexelekto or uncontrolled) was enhance
in PCa after exposure to Anxa2 (unpublished observations). AXL
binds to and is activated by the growth factor growth arrest–specific
6 (GAS6) [16]. In many systems, including HSCs, GAS6 inhibits cel-
lular proliferation and enhances cell survival [17–22]. Intriguingly,
GAS6 expressed by stromal cells slows the cell cycling of HSCs [21].
In the present report, it is demonstrated that the engagement of
Anxa2rs on PCa stimulates the expression of AXL receptors. In con-
trast with previous reports, we found that GAS6 inhibits PCa pro-
liferation, a situation more closely mimicking that of HSCs. These
findings suggest that GAS6 may participate in the induction of tumor
cell dormancy so that disseminated cells shed from a primary tumor
may lie dormant for prolonged periods in marrow. These observations
suggest further parallels between the regulation of HSC function in
their endosteal niche and the formation of PCa bone metastases.
Materials and Methods
Cell Culture
PC3 (CRL-1435), DU145 (HTB-81), and LNCaP (CRL-1740)
PCa cell lines were obtained from the American Type Culture Col-
lection (Rockville, MD). The metastatic subline LNCaP C4-2B was
originally isolated from a lymph node of a patient with disseminated
bony and lymph node involvement [23]. SaOS2 (HTB-85) andMG63
(CRL-1427) osteosarcoma cell lines were also obtained from the Ameri-
can Type Culture Collection. PCa cell lines and osteosarcoma cell lines
were cultured inRPMI 1640 (Invitrogen,Carlsbad, CA) andDulbecco’s
modified Eaglemedium (Invitrogen), respectively. All cultures were sup-
plemented with 10% (vol./vol.) fetal bovine serum (FBS; Invitrogen)
and 1% (vol./vol.) penicillin-streptomycin (Invitrogen) and maintained
at 37°C, 5% CO2, and 100% humidity.
Human Osteoblasts
Human osteoblasts were established by explant culture from normal
human trabecular bone obtained from patients undergoing orthopedic
surgery in accordance with the University of Michigan’s Investigational
Review Board, as previously described [3].
Antibodies and Reagents
The anti-AXL antibody (clone 108724; mouse immunoglobulin G
subclass 1 [IgG1]) and the anti-Mer antibody (clone 125518; mouse
IgG1) were purchased from R&D Systems (Minneapolis, MN). The
anti-Anxa2 antibody (clone 5; mouse IgG1) was purchased from BD
Pharmingen (San Diego, CA). Zenon Alexa Fluor 488 and 555 anti-
body labeling kits were purchased from Molecular Probes (Eugene,
OR). The control antibodies for these investigations included IgG1
(clone X40; Becton Dickinson, San Jose, CA). The antibodies to phos-
phorylated p44/42 mitogen-activated protein (MAP) kinase (Thr202/
Tyr204), total p44/42MAP kinase, and horseradish peroxidase–labeled
goat anti-rabbit IgG (H + L) were obtained from Cell Signaling Tech-
nology (Danvers, MA). Anxa2 N-terminal peptide corresponding to
the 1 to 12 amino acids and a random peptide (TVLLHEICKSSL)
were synthesized, as previously detailed [15]. Recombinant human
GAS6 was kindly provided by Amgen (Thousand Oaks, CA).
Anxa2 Treatments
PCa cell lines (1 × 106 cells/well) were cultured in six-well plates in
RPMI medium (1 ml) without FBS for 5 hours. After serum starvation,
the cells were treated with 1 μg/ml of Anxa2 N-terminal peptide for
24 hours. The cells were analyzed for messenger RNA (mRNA) of AXL,
Sky, andMer by real-time quantitative reverse transcription–polymerase
chain reaction (QRT-PCR). In some cases, PC3 cells were analyzed for
surface expression of AXL and Mer by flow cytometry.
RNA Extraction and QRT-PCR
QRT-PCR was carried out using standard techniques. Briefly, total
RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA), and
first-strand complementary DNA was synthesized in a 20-μl reaction
volume using 0.4 μg of total RNA. Reverse transcript products were
analyzed by QRT-PCR in TaqMan Gene Expression Assays of several
target genes including GAS6, AXL, Sky, Mer, and β-Actin (Applied
Biosystems, Foster City, CA). QRT-PCR analysis was performed using
15.0 μl of TaqMan Universal PCR Master Mix (Applied Biosystems),
1.5 μl of TaqMan Gene Expression Assay, 1 μl of complementary
DNA, and RNAse/DNAse–free water in a total volume of 30 μl. All
sample concentrations were standardized in each reaction to exclude
false-positive results. Reactions without template and/or enzyme were
used as negative controls. The second-step PCR (95°C for 30 seconds
and 60°C for 1 minute) was run for 40 cycles after an initial single cycle
of 95°C for 15 minutes to activate the Taq polymerase. The PCR prod-
uct was detected as an increase in fluorescence using an ABI PRISM
7700 sequence detection system (Applied Biosystems). RNA quan-
tity (CR) was normalized to the housekeeping gene β-actin control
by using the formula CR = 2
(40 − C t of sample) − (40 − C t of control). The
threshold cycle (C t) is the cycle at which a significant increase in fluo-
rescence occurs.
Flow Cytometry
PC3 cells were stained with anti-AXL or anti-Mer antibody or isotype-
matched IgG control. Flow cytometric analyses were performed in a
FACS Vantage dual-laser flow cytometer (Becton Dickinson).
Western Blot Analyses
PC3 cells (1 × 106 cells/well) were cultured in six-well plates in RPMI
medium (1 ml) without FBS for 5 hours. After serum starvation, the
cells were treated with 1 μg/ml GAS6 for 5, 15, 30, 45, and 60 minutes.
In some cases, PC3 cells or SaOS2 cells were treated with 1 μg/ml GAS6
and/or 1 μg/ml Anxa2 for 60 minutes. The cells were extracted for pro-
tein and analyzed for phosphorylated p44/42 MAP kinase (Thr202/
Tyr204) by Western blot analysis. Total p44/42 MAP kinase was used
as an internal control for loading.
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Tissue Microarray and Immunostaining
Human prostate adenocarcinoma tissue microarray was purchased
from US Biomax (Rockville, MD). Tumors were graded using the
Gleason grading system and examined to identify areas of benign pros-
tate, PCa, and bone metastasis. The formalin-fixed, paraffin-embedded
tissues were deparaffinized and placed in a pressure cooker containing
0.01 M buffered sodium citrate solution (pH 6.0), boiled, and chilled
to room temperature for antigen retrieval. The slides were incubated
overnight at room temperature with anti-AXL antibody diluted 1:100.
In some cases, the slides were costained with anti-AXL antibody (pre-
stained with Zenon Alexa Fluor 555) and anti-Anxa2 antibody (pre-
stained with Zenon Alexa Fluor 488). A pathologist blinded to
the study analyzed the arrays, and staining intensity was ranked on a
scale from 0 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong inten-
sity staining).
Vertebral Body Transplants (Vossicles)
Vertebral body transplantations were performed, as previously de-
scribed [9]. Lumbar vertebrae were isolated from Anxa2+/+ or Anxa2−/−
mice 7 days after birth. The vertebrae were sectioned into single verte-
bral bodies (vossicles). Athymic (nude) mice were used as transplant
recipients. Four vossicles were implanted per mouse into subcuta-
neous pouches. Before implantation, PC3 cells were introduced into
both Anxa2+/+ and Anxa2−/− vossicles by injection of 1 × 104 cells in
10 μl of PBS. At 30 days after implantation, vossicles were collected
and stained with anti-AXL antibody or isotype-matched IgG control.
GAS6 ELISA
Antibody sandwich ELISAs were used to measure GAS6 secreted
by human osteoblasts and osteosarcoma cell lines SaOS2 and MG63
(4 × 104 cells) into serum-free cell culture medium (R&D Systems).
In some cases, after 24 hours of serum starvation, PC3 cells in 100 μl
of RPMI 1640 supplemented without FBS were overlaid at 0 to 4 ×
104 cells per well onto the osteoblasts directly. GAS6 levels were nor-
malized to total protein in the cell culture–conditioned medium.
Transwell Invasion Assays
Cell invasion into a reconstituted extracellular matrix coating of
Matrigel laid over polyethylene terephthalate membranes with an
8-μm pore size was performed in dual-chambered invasion plates
(BD Biosciences, San Jose, CA) as previously described [24,25]. As-
sayed cells were placed in the upper chamber (1 × 105 cells/well) in
serum-free RPMI. Spontaneous invasion was compared with inva-
sion supported by GAS6 (0-1 μg/ml). At termination of the assay
(24 hours), chambers were removed, 40 μl of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml; Sigma-Aldrich,
St. Louis, MO) was added to the top well, and 80 μl of MTTwas added
to the bottom wells before incubation for an additional 4 hours at 37°C.
After completely removing residual medium or cells from the top cham-
ber, the purple residues were released from the bottom of the invasion
chambers, inside the invasion matrix, and from the bottom of the upper
chamber with 1 ml of isopropanol (Sigma-Aldrich). The invasion cham-
bers were rocked for 30minutes at a medium speed before reading 100 μl
from each well on a multiwell scanning spectrophotometer (Molecular
Devices, Sunnyvale, CA) at OD450.
Proliferation Assays
PC3 cells were plated into triplicate 96-well plates at a concentration
of 5000 cells per well (100 μl per well) in growth medium with 0.1%
FBS. After 24 hours, cells were treated with serial doses of rhGAS6
(0-1 μg/ml). In some cases, proliferation of PC3 cells in response of
GAS6 and/or Anxa2 was examined with/without 10 μM of U0126
for 1 hour (MAPK kinase [MEK] 1/2 inhibitor; Cell Signaling Tech-
nology). Thereafter, the cultures were incubated in an atmosphere of
5% CO2 and 95% O2 at 37°C for 3 days. Proliferation was quantified
using sodium 3′-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-
methoxy-6-nitro)benzene-sulfonic acid hydrate (XTT) colorimetric
assay (Sigma-Aldrich). Optical intensities were read on a multiwell
scanning spectrophotometer at OD492 (Molecular Devices).
Apoptosis Assays
PC3 cells (1 × 106 cells/well) were cultured in six-well plates in
RPMImedium (1 ml) without FBS for 5 hours. After serum starvation,
the cells were treated with 1 μg/ml of GAS6 for 24 hours. In certain
cases, PC3 cells (1 × 105 cells/well) were cultured in six-well plates in
RPMI medium (1 ml) with 5% FBS for 5 hours. Thereafter, the cells
were treated with 1 μg/ml GAS6 for 24 hours. In some cases, PC3 cells
were treated with 1 μg/ml of Anxa2 peptide for 24 hours before GAS6
treatment. After 24 hours of incubation, the cells were treated with
Taxotere (0.4 μg/ml) for 48 hours. Cells were stained for apoptosis
using annexin V PE (BD Biosciences) and 7AAD (BD Biosciences),
according to the manufacturer’s protocol. Apoptotic cells were quan-
tified by flow cytometry.
Cell Cycling Assays
Cell cycle status of PC3 cells treated with Anxa2 and/or GAS6
were analyzed by FACS using Hoechst 33342 (Molecular Probes)
and Pyronin Y (PY; Sigma-Aldrich) staining methods, as previously
described [26]. Briefly, PC3 cells (1 × 106 cells per well) were cultured
in six-well plates in RPMI medium (1 ml) without FBS for 5 hours
and were treated with 1 μg/ml of GAS6 or vehicle for 48 hours. In
some cases, PC3 cells were treated with 1 μg/ml of Anxa2 peptide
for 24 hours before GAS6 treatment. Thereafter, cells were incubated
in 2 μg/ml of Hoechst 33342 for 45 minutes and were incubated in
4 μg/ml of PY for another 45 minutes. The cell cycle state was analyzed
by flow cytometry. The cells that expressed lowHoechst 33342 and low
PY, low Hoechst 33342 and high PY, and high Hoechst 33342 and
high PY were determined as G0, G1, and S/G2/M states, respectively.
Quantification of Immunohistochemical Stains and
Western Blots
The staining intensities of immunohistochemistry slides and the den-
sities of the Western blot bands were quantified with ImageJ software
(version 1.40; National Institutes of Health, Bethesda, MD).
Statistical Analyses
All in vitro experiments were performed at least three times with simi
lar results. Results from representative assays are shown. Numerical
data are expressed as mean ± SD. Statistical analysis was performed
by analysis of variance or Student’s t test using the GraphPad Instat sta-
tistical program (GraphPad Software, San Diego, CA) with significance
at P < .05. For the QRT-PCR assays, a Kruskal-Wallis test and Dunn’s
multiple comparisons tests were used with the level of significance set
at P < .05.
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Figure 1. Anxa2-induced AXL family in PCa. (A) AXL, Sky, and Mer mRNA levels of PCa cell lines (LNCaP, C4-2B, PC3, and DU145) were
determined by real time RT-PCR. Data were normalized to β-actin and are presented as mean ± SD from three independent PCRs. (B) PCa
cell lines (LNCaP, C4-2B, PC3, and DU145) were treated with 1 μg/ml of N-terminal Anxa2 peptide for 24 hours, and RNA was isolated. The
levels of mRNA were determined by real-time RT-PCR. Data were normalized to β-actin and presented as the mean ± SD from three in-
dependent PCRs. *Significant difference from vehicle treatment. (C) Representative flow cytometric analyses of AXL and Mer expression
on PC3. PC3 cells were treated with 1 μg/ml of an N-terminal Anxa2 peptide for 24 hours. The expression levels of AXL and Mer were
determined by flow cytometry. Data are presented as mean ± SD from triplicate determinations. Data are presented as the mean ± SD
from three independent experiments. *Significant difference from vehicle treatment.NS indicates not significant. (D) PC3 cells were cultured
in medium without FBS for 5 hours. After serum starvation, the cells were treated with 1 μg/ml of GAS6 for 5, 15, 30, 45, and 60 minutes.
Total protein was extracted and analyzed byWestern blot for phosphorylated Erk1/2. Total Erk1/2 was used as an internal control for loading.
(E) PC3 cells and SaOS2 cells were cultured in medium without FBS for 5 hours. After serum starvation, the cells were treated with 1 μg/ml
of Anxa2 and/or 1 μg/ml of GAS6 for 60 minutes. Total protein was extracted and analyzed byWestern blot for phosphorylated Erk1/2. Total
Erk1/2 was used as an internal control for loading.
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Results
Anxa2 Stimulates PCa Expression of the AXL Subfamily of
Tyrosine Kinase Receptors
Previously, we determined that Anxa2 expressed by osteoblasts
plays a central role in niche selection by HSCs and in PCa metastasis
[9,15]. To explore the interaction of Anxa2 and the AXL family of
RTKs (AXL, Sky, and Mer), we first examined the basal expression
levels of the AXL family of RTKs in PCa cell lines by QRT-PCR.
High-level AXL expression was observed in DU145 and PC3 cells,
whereas a low level of AXL expression was detected in LNCaP and
C4-2B cells (Figure 1A). In comparison, higher Sky andMer expression
Figure 2. PCa expresses AXL. (A) Representative elements of a tissue microarray in PCa stained with anti-AXL antibodies. IgG staining
control not shown. (B) Quantitative analysis of data presented in (A). (C) Representative elements of a tissue microarray in metastatic
PCa stained with anti-AXL antibody. Original magnification, ×20. Scale bar, 100 μm.
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was detected in LNCaP and C4-2B cells than PC3 and DU145 cells
(Figure 1A).
Next, we expanded our studies to examine mRNA levels of AXL
and the other members of the AXL family of RTKs by PCa cell lines
after stimulation with Anxa2. Interestingly, mRNA expression of each
AXL family member was dramatically increased in DU145, PC3, and
C4-2B, but not LNCaP cells at 24 hours after Anxa2 stimulation
(Figure 1B). Flow cytometry was used to determine whether the
changes in mRNA levels correspond with alterations in cell surface ex-
pression of AXL family RTKs. For these studies, PC3 cells were chosen
because they expressed high basal levels of the AXL mRNA and re-
sponded robustly to Anxa2 stimulation (Figure 1, A and B). PC3 cells
were treated with Anxa2 for 24 hours, and cell surface receptor expres-
sion was evaluated. As shown in Figure 1C , cell surface expression
of AXL and Mer were easily distinguished from control IgG staining
(a suitable antibody for Sky expression was not identified [data not
presented]). More cell surface AXL expression was detected in Anxa2-
treated cells than in vehicle-treated cells (75.4 ± 1.3% vs 68.6 ± 0.5%,
P = .0012), whereas Mer expression was not altered (Figure 1C). To de-
termine whether the expression of the AXL family of RTKs is activated
in response to GAS6, an established ligand for all three Axl subfamily of
RTKs [16] and PC3 cells was treated with GAS6. Phosphorylation of
Erk1/2, a downstream effector of AXL signaling [16,27], after GAS6
treatment was evaluated by Western blot analysis. Data demonstrate
that GAS6 rapidly induces Erk1/2 phosphorylation in PC3 cells within
5 minutes (Figures 1D and W1A). In addition, GAS6 and Anxa2
showed synergic effects on Erk1/2 phosphorylation (Figures 1E and
W1B). However, no effects of Anxa2 and GAS6 on Erk1/2 phosphory-
lation in osteosarcoma cells were observed (Figures 1E andW1C). These
findings suggest that GAS6 activates the AXL family of tyrosine kinase
receptors in PCa cells.
The findings thus far suggest that AXL expression is regulated by
Anxa2. Because Anxa2 is highly expressed in marrow, brain, and lymph
nodes compared with other soft tissues [9,15], tissue microarrays were
used to correlate AXL expression with metastasis. Tumors were graded
using the Gleason grading system and examined to identify areas of be-
nign prostate and PCa. Staining of microarrays with antibody to AXL
revealed moderate-to-strong AXL protein expression with cytoplasmic
and nuclear localization in clinically localized PCa samples (Figure 2A).
AXL protein expression was enhanced with increasing tumor grade (Fig-
ure 2, A and B). In addition, the bone metastatic lesions showed in-
tense AXL expression compared with lymph node metastatic lesions
(Figure 2C). To further address the relationship between AXL andAnxa2
in PCa, tissue microarrays were analyzed by costaining with anti-AXL
antibody and anti-Anxa2 antibody. Interestingly, the expression of
AXL was inversely proportional to the expression of Anxa2 in the pri-
mary site (Figure 3). These data correlate to the previous observations
that the loss of Anxa2 expression seems to be specific for PCa disease
[28–33]. These data suggest that PCa express AXL on their surface
and that AXL expression may reflect tumor aggressiveness.
The data presented thus far also suggest that Anxa2 regulates the ex-
pression of AXL in PCa in vitro. To determine whether Anxa2 regulates
AXL expression in PCa cells in vivo, we took advantage of an osteogenic
assay in which neonatal skeletal elements are transplanted subcutane-
ously into recipient mice to form bone in vivo (e.g., vertebral body
or “vossicles”) [34,35]. Here, vertebral bodies excised from Anxa2+/+
or Anxa2−/− animals were seeded with human PCa cells (PC3) before
vossicle implantation into immunodeficient animals (Figure 4A). After
Figure 3. Interaction between the expression of AXL and Anxa2 in PCa. Representative elements of a tissue microarray in PCa costained
with anti-AXL antibodies and anti-Anxa2 antibodies. Nuclei were identified by 4′,6-diamidino-2-phenylindole. Original magnification, ×20.
Scale bar, 100 μm.
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1 month, the vossicles were dissected, and the expression of AXL by the
implanted PC3 was evaluated by immunohistochemistry. Significantly
more AXL expression by PC3 cells was observed when the cancer cells
were implanted into vossicles that expressed Anxa2 (Figure 4, B and C).
Real-time PCR examination of the native bones of these animals did
not detect significant human ALU signals derived from the human
PCa cells, suggesting that the PCa cells did not migrate away from
the Anxa2−/− vossicles (data not presented). These data suggest that
Anxa2 regulates the expression of AXL in PCa in vivo and is critical
for PCa growth in bone.
Osteoblasts Express GAS6
GAS6 is one of the known ligands for the AXL family of RTKs. Be-
cause osteoblasts represent critical cells that participate in the establish-
ment of the HSC niche and express Anxa2, we explored whether
osteoblasts also express GAS6. Primary human osteoblasts and the
Figure 4. Anxa2-induced AXL expression of prostate cancer in vivo. (A) Experimental design. (B) PC3 cells (1 × 104 cells per 10 μl) were
injected into vertebral bodies (vossicles) derived from Anxa2+/+ and Anxa2−/− mice and transplanted into immunodeficient mice (n = 12).
At 1 month after transplantation, the vossicles were dissected, and the AXL expression in the vossicles was evaluated by immunohisto-
chemistry. Original magnification, ×60. Scale bar, 100 μm. (C) Quantitative analysis of AXL staining in (B). Data are presented asmean± SD.
*Significant difference from AXL staining of PCa grown in Anxa2+/+ vossicles.
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osteoblast-like human osteosarcoma cell lines SaOS2 and MG63 were
evaluated by QRT-PCR for the expression of GAS6 mRNA. The data
suggest that GAS6 mRNA was most strongly expressed by primary
human osteoblasts (Figure 5A). To validate that GAS6 mRNA is trans-
lated into a mature secreted protein, GAS6 levels were evaluated in
serum-free cell culture medium conditioned by primary human osteo-
blasts and human osteoblast-like cells. Primary human osteoblasts
produced the most GAS6 in culture (145.6 ± 13.6 pg/ml) as detected
by ELISA, followed by SaOS2 (1.5 ± 2.3 pg/ml) in a 48-hour period
(Figure 5B). Next, to determine whether GAS6 synthesis occurs in re-
sponse to PCa cells, cocultures of PC3 cells and the primary human
osteoblasts were established, and cell culture–conditioned medium
was collected after 48 hours. In the direct cell-to-cell contact cocultures,
the productions of GAS6 were significantly stimulated compared with
the primary human osteoblasts alone (Figure 5C). These data suggest
that osteoblastic cells express GAS6, that human osteoblasts secrete
GAS6, and that GAS6 synthesis occurs in response to PCa cells. Little
to no GAS6, however, was identified in cell culture medium condi-
tioned by the human osteosarcoma cell lines.
GAS6 Regulates the Invasion, Proliferation, Survival, and
Cell Cycling of PCa
In many systems, the binding of GAS6 to AXL alters cellular func-
tions including migration, proliferation, and survival [36–41]. We evalu-
ated the effect of GAS6 on PCa in each of these cellular functions.
First, it was determined using in vitro invasion chambers that PCa
cells migrate toward GAS6 (Figure 6A).
Next, proliferation assays demonstrated that GAS6 inhibited the
proliferation of PC3 and DU145 cells in a dose-dependent manner
(Figure 6B). To further address potential mechanisms, proliferation of
PC3 in response to GAS6 and/or Anxa2 with/without U0126 (MEK
1/2 inhibitor) treatment was examined. As before, GAS6 inhibited the
proliferation of PC3, whereas no further enhancements were observed
in response to Anxa2 treatment (Figure 6C). In addition, when the cells
were treated with Anxa2 and GAS6, the proliferation of PC3 cells was
inhibited (Figure 6C). However, when the cells were pretreated with
U0126, all of those effects were offset (Figure 6C).
The observation that GAS6 reduced PCa proliferation in vitro
prompted our studies to determine whether GAS6 also protects PCa
from apoptotic cell death. For these studies, PCa cells were extensively
washed and then starved serum in the presence or absence of GAS6.
After 24 hours, apoptotic cells were detected by flow cytometry using
annexin V staining. The data demonstrate that fewer apoptotic cells
were detected in GAS6-treated cells than controls (Figure 6D, left).
To determine whether the reduced proliferation of PCa cells in response
to GAS6 protects PCa cells from chemotherapy, the viability of PC3
cells subjected to chemotherapy was evaluated. PC3 cells were incu-
bated with Taxotere in the presence or absence of GAS6. Annexin V
staining was used to evaluate apoptosis induction. The inclusion of
GAS6 in PCa cell cultures treated with Taxotere reduced the levels of
annexin V staining compared with vehicle controls (Figure 6D, right).
To further address the relationship between Anxa2 and GAS6 in the
induction of PCa chemoresistance, PC3 cells were treated with Anxa2
and/or GAS6 before Taxotere treatment. Surprisingly, Anxa2 did not
protect PC3 cells from chemotherapy, but when the PC3 cells were
treated with Anxa2 and GAS6, the effects on protection of PC3 cells
from chemotherapy were enhanced (Figure 6E).
Finally, to address whether GAS6 induces PCa into a dormant state,
cell cycling states were evaluated by flow cytometry in the absence and
Figure 5. Osteoblasts express GAS6. (A) GAS6 mRNA levels in
human osteoblasts and the osteosarcoma cell lines SaOS2 and
MG63 were determined by real-time RT-PCR. Data were normalized
to β-actin and presented as mean ± SD from three independent
PCRs. *Significant differences from mRNA expressed by human
osteoblasts. (B) Humanosteoblasts, SaOS2, andMG63 (4×104 cells
per well) were plated in 24-well plates in Dulbecco’s modified Eagle
medium (1 ml) without serum. (C) PC3 cells (0-4 × 104 cells) were
seeded directly onto primary human osteoblast monolayers (4 ×
104 cells) in 24-well tissue culture plates in serum-free conditions.
At 48 hours, culture medium was collected. The levels of GAS6
were determined by ELISA, and supernatants were normalized by
total protein concentration. Data are presented as mean ± SD from
triplicate determinations. *Significant difference from human osteo-
blasts alone.
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Figure 6. GAS6 regulates the invasion, proliferation, and apoptosis of PCa cell lines. (A) Matrigel invasion assays were performed to
measure the treatment effect of GAS6 (0-1 μg/ml) on PC3 cell invasion. Data are presented as mean ± SD from triplicate determinations.
*Significant different from spontaneous invasion. GAS6 inhibits cell proliferation in PCa cell lines (DU145 and PC3) in a dose-dependent
manner. (B) DU145 and PC3 were seeded at 5000 cells per well in 96-well plates and were cultured with 0.1% FBS in the presence or
absence of GAS6 (0-1 μg/ml). After 48 hours, cell proliferation was assessed using the XTT assay. Data are presented as mean ± SD
from triplicate determinations. *Significant difference from vehicle treatment. (C) PC3 were seeded at 5000 cells per well in 96-well
plates and were cultured with 0.1% FBS in the presence or absence of GAS6 (1 μg/ml) and/or Anxa2 (1 μg/ml). In some cases, the cells
were pretreated with U0126 (10 μM) for 1 hour. After 48 hours, cell proliferation was assessed using XTT assay. Data are presented as
mean ± SD from triplicate determinations. The effects of GAS6 on apoptosis and drug resistance of PCa were measured by annexin V
staining. (D) Left: PC3 were treated with GAS6 (1 μg/ml) in serum-free medium for 24 hours. The percentage of apoptotic cells was
assessed by flow cytometry. Right: PC3 were incubated with Taxotere after 24 hours with GAS6 (1 μg/ml) treatment in medium contain-
ing 5% FBS. Data are presented as mean ± SD from triplicate determinations. *Significant difference from vehicle treatment. (E) PC3
were incubated with Taxotere after 24 hours with GAS6 (1 μg/ml) and/or Anxa2 (1 μg/ml) treatment in medium containing 5% FBS. After
48 hours of incubation, the percentage of apoptotic cells was assessed by flow cytometry. Data are presented as mean ± SD from
triplicate determinations.
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presence of GAS6 and/or Anxa2. GAS6 increased the fraction of cells in
G0 and decreased the fraction in the G1 and S/M/G2 states (Table 1).
However, GAS6 and Anxa2 showed no synergic effects on cell cycling
states (Table 1).
Taken together, these data suggest that GAS6 supports the PCa in-
vasion, inhibits PCa proliferation through the MAPK signaling path-
way, prevents apoptosis of PCa, protects PCa against chemotherapy,
and regulates the cell cycling state of PCa. These data also suggest that
the interaction of PCa with Anxa2 in the endosteal niche enhances their
receptivity to GAS6, further suggesting a role for GAS6 in regulating
the dormancy of PCa disseminating to the marrow.
Discussion
Several investigators have shown that the members of the AXL
subfamily of RTKs—AXL, Sky, and Mer—are expressed in vari-
ous types of cancers [40–49]. In result, it has been suggested that
the AXL family RTKs may prove to be rationale targets for cancer
therapy [49].
In this study, it was shown that the GAS6/AXL axis plays a role in
regulating the invasion, proliferation, and survival of PCa. Initially, it
was demonstrated that binding Anxa2 increases the expression of the
AXL family of RTKs at an mRNA level, indicating a direct relation-
ship between Anxa2/Anxa2r axis and the AXL subfamily of RTKs.
Table 1. Effects of Anxa2 and GAS6 on the Cell Cycling State of PC3.
Cell Cycle % Cell (P vs Vehicle Treatment)
Vehicle Anxa2 GAS6 Anxa2 + GAS6
G0 28.3 ± 0.7 33.0 ± 0.7 (P = .0011) 32.9 ± 0.7 (P = .0011) 32.0 ± 1.4 (P = .0151)
G1 58.9 ± 0.2 56.5 ± 0.7 (P = .0036) 56.7 ± 0.3 (P = .0003) 57.4 ± 1.4 (P = .1487)
S/M/G2 12.8 ± 0.5 10.5 ± 0.0 (P = .0014) 10.4 ± 0.4 (P = .0029) 10.6 ± 0.2 (P = .0024)
PC3 were treated with Anxa2 (1 μg/ml) and/or GAS6 (1 μg/ml) in serum-free medium for 48 hours. Cell cycling states of PC3 were assessed by flow cytometry. Data are presented as mean ± SD from
triplicate determinations. Significantly different from vehicle treatment.
Figure 7. Dormancy of PCas is regulated by Anxa2 and GAS6 in the marrow. PCa cells display a remarkable ability to invade and survive in
bone. The metastatic process is functionally similar to the migrational or “homing” behavior of hematopoietic cells to the bone marrow.
Numerous molecules have been implicated in regulating HSC homing, participating as both chemoattractants and regulators of cell
growth. Our previous work has demonstrated that PCa cells, like HSCs, use the CXC chemokine stromal–derived factor 1 (SDF-1 or
CXCL12) and its receptor (CXCR4 or CXCR7/RDC1 [not shown]) to gain access to the bone marrow for metastasis formation and growth
in bone. Engagement of SDF-1 receptors on PCa cells leads to increased expression of αvβ3 integrins, CD164, and Anxa2 that bind PCa to
osteoblasts. Binding of PCa cells to Anxa2 induces transcription of the GAS6 family of receptors including AXL. AXL binding to GAS6
produced by osteoblasts induces quiescence of PCa cells and protects them from chemotherapy.
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Subsequently, it was determined that the expression levels of AXL were
significantly increased during metastasis to sites known to express high
levels of Anxa2. We also demonstrated that GAS6 regulates invasion of
PCa, inhibits PCa proliferation, protects PCa from chemotherapy, and
alters the cell cycling state of PCa. It was also demonstrated that human
osteoblasts express GAS6. Together, these data strongly suggest that the
GAS6/AXL axis plays a regulatory role in the growth of PCa in the
bone marrow. Furthermore, this regulation is achieved by 1) enhancing
the PCa expression of the AXL family of RTKs when PCa cells bind to
Anxa2 on osteoblasts and 2) secreting GAS6 as a paracrine signal by
osteoblasts in the endosteal niche (see model, Figure 7).
In marrow, GAS6 is thought to be constitutively produced by fibro-
blasts and other stromal cells that support hematopoiesis [21,50]. It
has been widely reported that GAS6 alters proliferation and survival
of several different types of cancer cells [36–38,40,41]. The present
study demonstrated that GAS6 inhibited the proliferation of PCa cells
while protecting them from apoptotic cell death. However, these data
are in conflict with those reported previously using similar cells. For
example, the report by Sainaghi et al. [40] suggests that GAS6/AXL
interactions are mitogenic for human PCa cell lines [51,52]. More-
over, the effect was proportional to AXL expression and not due to
the inhibition of apoptosis [40]. Wu et al. [41] also reported that over-
expression of the Mer occurs in a subset of PCa cells including the
DU145 cell line. Here, too, activation ofMer did not result in increased
proliferation. Rather, it stimulated the production of endocrine fac-
tors including chemokines such as IL-8 through transcriptional induc-
tion of the MEK/ERK/Jun/Fos pathway. It is unclear why our results
differ from these previous reports. However, our results are in keep-
ing with the concept that metastatic PCa parasitize the HSC niche
[53]. Similarly, we have also shown that GAS6 supported survival,
prevented apoptosis from chemotherapy, and regulated cell cycling in
Mer-positive B-cell precursor acute lymphoblastic leukemia [54].
Our recent studies have shown that Anxa2, in addition to SDF-1, is
produced by osteoblasts and plays an important role in the adhesion of
HSCs to the endosteal niche [15,55]. The concept of “stem cell niche”
has been proposed based on observations that HSCs are found in dis-
crete areas in the bone marrow [56]. The stem cell niche is thought to
regulate HSC self-renewal, proliferation, and differentiation through
production of cytokines and cellular signals that are initiated by cell-to-
cell adhesive interactions between HSCs and the components of the
stem cell niche. Recent studies have demonstrated that osteoblasts com-
prise a crucial component of the HSC niche, “the endosteal niche,” and
cells of other lineage, including endothelial cells, probably participate in
these stem cell functions. HSCs express the Anxa2r as well as CXCR4,
which bind Anxa2 and SDF-1, respectively, and enable homing of
HSCs to the endosteal niche. Similarly, PCa cells express both these
molecules and seem to also use the same niche when homing to the
bone marrow [9].
By-in-large, the role of the niche is thought to be the induction HSC
dormancy. If metastatic PCa cells occupy a similar or the same ecologi-
cal niche as HSCs themselves, then it is likely that the initial role of the
HSC niche will be to induce dormancy in metastatic cells. In this study,
GAS6 inhibited PCa proliferation, supported PCa survival, prevented
PCa apoptosis from chemotherapy, and regulated cell cycling of PCa.
Thus, these data suggest that GAS6/AXL axis is a potential target to
metastasized PCa therapy. Previously, it was demonstrated that GAS6
expression by stromal cells reduces cell cycling of HSCs [21]. Our ob-
servations suggest a similar response by PCa. Although further study
will clearly be needed, our results suggest that the activation of GAS6
receptors on PCa in the marrow environment may play a critical role as
a molecular switch to establish dormancy.
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Figure W1. Quantitative analysis of Western blots. The densities of the Western blot bands were quantified with ImageJ software.
(A) Quantitative analysis of phosphorylated Erk1/2 in PC3 cells that were treated with GAS6 in Figure 1D. (B) Quantitative analysis of phos-
phorylated Erk1/2 in PC3 cells that were treated with Anxa2 and/or GAS6 in Figure 1E . (C) Quantitative analysis of phosphorylated Erk1/2 in
SaOS2 cells that were treated with Anxa2 and/or GAS6 in Figure 1E . Data are presented as mean ± SD from triplicate determinations.
